• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Eisai, Clinigen partner on patient access program in Germany

Eisai, Clinigen partner on patient access program in Germany

September 9, 2013
CenterWatch Staff

Eisai EMEA, an R&D based pharmaceutical company, has established a named patient access program to ensure patients continue to receive an uninterrupted supply of the anti-epilepsy drug Fycompa (perampanel), following the temporary suspension of commercial distribution in Germany. The access program will be managed by Clinigen Global Access Programs (GAP), a U.K.-headquartered specialty global pharmaceutical company.

The access program is not expected to be utilized until the beginning of 2014, as there are sufficient stocks of Fycompa in Germany to meet demand until the end of December. All patients will receive an uninterrupted supply at no cost to the German healthcare system. The access program will remain in place until commercial distribution resumes. The company intends to submit Fycompa for reassessment at the earliest opportunity.

"As approximately 3,000  to 4,000 people with epilepsy in Germany have benefitted from this treatment since its launch in September 2012, our priority is to ensure that these patients continue to receive an uninterrupted supply of the treatment,” said Gary Hendler, president and chief executive officer, Eisai EMEA. “Eisai has partnered with Clinigen GAP so patients can continue to receive Fycompa after the temporary suspension has come into effect and German stock of the drug is exhausted at the end of the year."

Discovered and developed by Eisai in the U.K. and Japan, Fycompa is the first and only approved anti-epileptic drug in Europe with a mode of action that selectively targets AMPA receptors, thought to play a central role in seizure generation and spread. The successful treatment of partial-onset seizures remains a challenge for patients and physicians, as over 30% of patients do not achieve seizure freedom despite appropriate therapy with anti-epileptic drugs.

Fycompa was granted marketing authorization by the E.C. July 2012 and is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing